PRESS RELEASE WASHINGTON.

He is also the Director of the NIH PGY2 Oncology Pharmacy Residency Plan and a medical investigator on 35 NCI-sponsored clinical trials, test­ining new and innovative ways to treat cancer. He is a graduate of the University of California SAN FRANCISCO BAY AREA and finished his PGY1 Pharmacy Practice Residency there before shifting to the NIH, where he completed his PGY2 Oncology Pharmacy Residency. Zlott has been active within APhA since he was students highly, having served in a true number of positions inside APhA–ASP, includ­ing National President.New diagnostic technologies for digestive disorders including colorectal cancers screening, gastroparesis and heartburn. The impact of the legal, regulatory and reimbursement environment on the uptake and advancement of new GI systems. The converging forces that produce the GI market a viable and appealing investment opportunity. Areas of chance in GI for purchase and innovation. The AGA is committed to improving the treatment of individuals with digestive diseases, and is focused on outcomes and bringing cutting-edge, appropriate treatments to patients with gastrointestinal conditions. This conference is being held in collaboration with Kleiner Perkins Caufield & Byers. When:March 19 & 20, 2010 Where:Four Months Silicon Valley, East Palo Alto, CA For a total list and program of faculty, review the meeting brochure at..